secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001104659-25-107008
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure Q3 net loss $8.6M; cash $29.1M, PoC data for two ADCs expected H1 2026
-------------------------------------------------------------------------------

- Cash $29.1M as of Sep 30, 2025, down from $68.6M; expected to fund operations into mid-2026.
- Net loss $8.6M in Q3 2025 vs $11.5M in Q3 2024; R&D spend down to $6.1M from $8.8M.
- SIM0505 (CDH6 ADC) US enrollment began Oct 2025 at mid-tier dose; PoC data readout expected H1 2026.
- LNCB74 (B7-H4 ADC) received FDA protocol amendment for higher dose cohorts; PoC data also H1 2026.
- $12M upfront license fee to Simcere Zaiming for SIM0505 rights contributed to cash burn.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000110465925107008/0001104659-25-107008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000110465925107008/nxtc-20251105x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-107008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer